吉非替尼
表皮生长因子受体
医学
腺癌
癌症研究
酪氨酸激酶抑制剂
酪氨酸激酶
癌
生长因子受体
肺
肺癌
病理
肿瘤科
内科学
受体酪氨酸激酶
T790米
表皮生长因子
免疫组织化学
埃罗替尼
肺腺癌
受体
癌症
作者
Monalisa Hui,Shantveer G Uppin,Bala Joseph Stalin,Gundeti Sadashivudu
出处
期刊:Lung India
[Medknow Publications]
日期:2018-03-01
卷期号:35 (2): 160-160
被引量:6
标识
DOI:10.4103/lungindia.lungindia_347_17
摘要
A subset of non-small cell lung carcinoma (NSCC) harbor active mutations of epidermal growth factor receptor (EGFR). In these, EGFR tyrosine kinase inhibitors (EGFR-TKIs) are recommended as the first-line treatment. Though drug resistance is inevitable, histological transformation to small cell lung carcinoma (SCLC) is a rare mechanism for acquired resistance. Here we report one such rare case of histological transformation of pulmonary adenocarcinoma to small cell lung carcinoma in 46 year old male treated with Gefitinib.
科研通智能强力驱动
Strongly Powered by AbleSci AI